A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
NCT06660667
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
66
Enrollment
INDUSTRY
Sponsor class
Conditions
Neovascular Age-related Macular Degeneration
Interventions
BIOLOGICAL:
SAR402663
DRUG:
Diluent
Sponsor
Sanofi